Talphera Inc. Reports Q2 2025 Financial Results; Cash Operating Expenses Guidance Reduced to $16-$17 Million from $17-$19 Million
Reuters
Aug 15
<a href="https://laohu8.com/S/TLPH">Talphera Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Financial Results; Cash Operating Expenses Guidance Reduced to $16-$17 Million from $17-$19 Million
Talphera Inc., a specialty pharmaceutical company, has announced its second quarter 2025 financial results. The company reported a cash and cash equivalents balance of $6.8 million as of June 30, 2025. Talphera also provided an expense guidance for 2025, forecasting cash operating expenses, excluding stock-based compensation, to be in the range of $16 million to $17 million. This is a reduction from the previously provided range of $17 million to $19 million. In terms of business updates, Talphera has made progress in its NEPHRO CRRT registration trial, with 15 patients enrolled and completion projected by the end of the year. The company also announced the closing of the first tranche of a $4.9 million financing as part of a three-tranche deal for up to $14.8 million. The financing was led by existing investors and includes a member of management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF51276) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.